Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31164812 | 0.85 | NPC1 (0.61) | NPC1RAB9ACA12CA9CHRNB2 | |
| SCHEMBL20794233 | 0.84 | MEP1B (0.49) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2095207 | 0.83 | NPC1 (0.59) | NPC1RAB9ACA12CA9CHRNB2 | |
| SCHEMBL15095805 | 0.83 | ALDH1A1 (0.46) | NPC1RAB9ACA12CA9CHRNB2 | |
| SCHEMBL9657280 | 0.82 | MEN1 (0.46) | NPC1RAB9ACA12CA9CHRNB2 | |
| SCHEMBL4018145 | 0.82 | LMNA (0.56) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL11378934 | 0.82 | NPC1 (0.53) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL23805545 | 0.82 | CHRNB2 (0.58) | NPC1RAB9ACA12CA9CHRNB2 | |
| SCHEMBL20794226 | 0.82 | MEP1B (0.54) | RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2097870 | 0.81 | NPY5R (0.56) | NPC1RAB9AKMT2AABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| WO-2020237169-A1 | SEMI-SYNTHETIC ANALOGUES OF EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2020-07-16 | — | — | US | disclosed |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2019-03-07 | — | — | US | disclosed |
| US-10040754-B2 | Cellulose acylate film, novel compound, polarizing plate and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2018-08-07 | — | — | US | disclosed |
| US-9907796-B2 | Methods of treating tumoral diseases, or bacterial or viral infections | INHIBIKASE THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| CN-105646288-A | Preparation method of carbamate derivatives | 江苏强盛功能化学股份有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-104428714-A | Microlens fabrication method | FUJIFILM CORP | 2015-03-18 | — | — | CN | disclosed |
| CN-104317164-A | Black curable composition | FUJIFILM CORP | 2015-01-28 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7323562-B2 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | LPAR1, LPAR2, LPAR4 | NPC1 520/4885RAB9A 1177/4885CA12 4654/4885 |
| US-10040754-B2 | Cellulose acylate film, novel compound, polarizing plate and liquid crystal display device | NR1D1, NR1H2, NR1D2 | NPC1 456/4885RAB9A 4375/4885CA12 808/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NPC1 3130/4885RAB9A 3153/4885CA12 3179/4885 |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | LPAR1, LPAR2, LPAR4 | NPC1 520/4885RAB9A 1177/4885CA12 4654/4885 |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | NPC1 76/4885RAB9A 2609/4885CA12 2111/4885 |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | NPC1 76/4885RAB9A 2609/4885CA12 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.